Evidence map›Paper›PMID 42603857›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2026

LCN2 Associated With the Bidirectional Cardio-Kidney Link in Patients With Type 2 Diabetes and Cardiovascular-Kidney-Metabolic Syndrome.

Xinmei Huang, Yueyue Wu, Lihong Wang, Junjie Jia, Tianyi Wu, Wenjuan Liu, Yi Wang, Yeyao Fan, Wei Gong, Li Zhang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Xinmei HuangDepartment of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, China.
Yueyue WuDepartment of Endocrinology, Shanghai Fifth People's Hospital, Fudan University, Shanghai, China.
Lihong WangDepartment of Endocrinology and Metabolism, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
Junjie JiaDepartment of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, China.
Tianyi WuDepartment of Endocrinology, Shanghai Fifth People's Hospital, Fudan University, Shanghai, China.
Wenjuan LiuDepartment of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, China.
Yi WangDepartment of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, China.
Yeyao FanDepartment of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, China.
Wei GongDepartment of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, China.
Li ZhangDepartment of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, China.
Jun LiuDepartment of Endocrinology and Metabolism, Shanghai Fifth People's Hospital, Fudan University, Shanghai, China.
Shufei ZangDepartment of Endocrinology and Metabolism, Shanghai University of Medicine & Health Sciences Affiliated Zhoupu Hospital, Shanghai, China.
Zhaoyun ZhangDepartment of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Despite the well-established epidemiological association between diabetic kidney disease (DKD) and coronary artery disease (CAD) in patients with T2DM, which reflects a core feature of cardiovascular-kidney-metabolic (CKM) syndrome, the underlying molecular mechanisms connecting these 2 conditions remain unclear. Within this integrated pathophysiological framework, the potential role of lipocalin-2 (LCN2) was investigated. MATERIAL AND METHODS A total of 917 participants with T2DM were stratified into an overall cohort and a BMI-, age-, and sex-matched sub-cohort. Serum LCN2 levels were measured. Immunohistochemistry was performed on cardiac and renal tissues from high-fat diet/streptozotocin-induced diabetic mice. Renal tubular (HK-2) and cardiomyocyte (H9c2) cells were treated with recombinant LCN2 to assess inflammatory responses. RESULTS DKD severity was identified as an independent risk factor for CAD in patients with T2DM. Serum LCN2 levels were significantly elevated in patients with DKD or CAD, and were closely correlated with DKD severity and B-type natriuretic peptide levels. Logistic regression analysis further indicated that an elevated serum LCN2 level served as an independent risk factor for the presence of DKD or CAD. Importantly, mediation analysis revealed that increased serum LCN2 may partially mediate the bidirectional association between DKD and CAD. Consistent with these clinical findings, animal experiments demonstrated concurrent upregulation of LCN2 in both the heart and kidney tissues of diabetic mice. Recombinant LCN2 dose-dependently increased interleukin-6 and tumor necrosis factor-a mRNA expression in HK-2 and H9c2 cells. CONCLUSIONS LCN2 may represent a potential biomarker and partial mediator between DKD and CAD in T2DM, potentially contributing to CKM-related organ crosstalk.

Indexed as

Cardio-Renal SyndromeDiabetes Mellitus, Type 2Lipocalin-2Metabolic SyndromeAgedAnimalsCoronary Artery DiseaseDiabetes Mellitus, ExperimentalDiabetic NephropathiesFemaleHumansKidneyMaleMiceMice, Inbred C57BLMiddle AgedLCN2 protein, humanLipocalin-2

Identifiers

PMID42603857
PMCPMC13492171

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.